Piper Jaffray Starts Adamas Pharmaceuticals (ADMS) at Overweight

Piper Jaffray initiates coverage on Adamas Pharmaceuticals (NASDAQ: ADMS) with a Overweight rating and a price target of $32.00.

Analyst David Amsellem comments, "Adamas has the potential to generate compelling cash flows over the long-term, driven by ADS-5102, an extended release (ER) form of amantadine for levodopa-induced dyskinesias (LID) associated with Parkinson’s disease (PD) treatment, and royalties from partner Forest/Actavis on two line extensions for Alzheimer’s blockbuster Namenda (aka memantine). We estimate that ADMS will reach profitability in 2018), and we believe there is compelling optionality associated with ADMS at a market cap of $325M."

For an analyst ratings summary and ratings history on Adamas Pharmaceuticals click here. For more ratings news on Adamas Pharmaceuticals click here.

Shares of Adamas Pharmaceuticals closed at $20.01 yesterday.

You May Also Be Interested In

• Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
• Travelers (TRV) PT Raised to $425 at Truist Securities; 'Upside on Top- and Bottom-Line Momentum'
• H.C. Wainwright Assumes Soluna (SLNH) at Buy